🚀 VC round data is live in beta, check it out!
Jasper Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jasper Therapeutics and similar public comparables like Atara Biotherapeutics, Radiopharm Theranostics, Lisata Therapeutics, Zhengye Biotechnology and more.
Jasper Therapeutics Overview
About Jasper Therapeutics
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Founded
2019
HQ
Employees
64
Website
Financials (LTM)
Market Cap
$39M
Jasper Therapeutics Financials
Jasper Therapeutics reported last 12-month revenue of —.
In the same LTM period, Jasper Therapeutics generated — in gross profit and had net loss of ($85M).
Revenue (LTM)
Jasper Therapeutics P&L
In the most recent fiscal year, Jasper Therapeutics reported revenue of — and EBITDA of ($75M).
Jasper Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($75M) | XXX | XXX | XXX |
| Net Profit | ($85M) | XXX | ($71M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jasper Therapeutics Stock Performance
Jasper Therapeutics has current market cap of $39M.
Market Cap Evolution
Jasper Therapeutics' stock price is $1.38.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $39M | 0.0% | XXX | XXX | XXX | $-2.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJasper Therapeutics Valuation Multiples
Jasper Therapeutics trades at 0.1x EV/EBITDA.
EV / Revenue (LTM)
Jasper Therapeutics Financial Valuation Multiples
As of March 21, 2026, Jasper Therapeutics has market cap of $39M.
Equity research analysts estimate Jasper Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jasper Therapeutics has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39M | XXX | $39M | XXX | XXX | XXX |
| EV (current) | ($11M) | XXX | ($11M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jasper Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jasper Therapeutics Margins & Growth Rates
Jasper Therapeutics' revenue in the last fiscal year grew by —.
Jasper Therapeutics' revenue per employee in the last FY averaged $0.0M.
Jasper Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jasper Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Atara Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Radiopharm Theranostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lisata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhengye Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Tvardi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jasper Therapeutics M&A Activity
Jasper Therapeutics acquired XXX companies to date.
Last acquisition by Jasper Therapeutics was on XXXXXXXX, XXXXX. Jasper Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jasper Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJasper Therapeutics Investment Activity
Jasper Therapeutics invested in XXX companies to date.
Jasper Therapeutics made its latest investment on XXXXXXXX, XXXXX. Jasper Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jasper Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jasper Therapeutics
| When was Jasper Therapeutics founded? | Jasper Therapeutics was founded in 2019. |
| Where is Jasper Therapeutics headquartered? | Jasper Therapeutics is headquartered in United States. |
| How many employees does Jasper Therapeutics have? | As of today, Jasper Therapeutics has over 64 employees. |
| Who is the CEO of Jasper Therapeutics? | Jasper Therapeutics' CEO is Jeet Mahal. |
| Is Jasper Therapeutics publicly listed? | Yes, Jasper Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Jasper Therapeutics? | Jasper Therapeutics trades under JSPR ticker. |
| When did Jasper Therapeutics go public? | Jasper Therapeutics went public in 2021. |
| Who are competitors of Jasper Therapeutics? | Jasper Therapeutics main competitors are Atara Biotherapeutics, Radiopharm Theranostics, Lisata Therapeutics, Zhengye Biotechnology. |
| What is the current market cap of Jasper Therapeutics? | Jasper Therapeutics' current market cap is $39M. |
| Is Jasper Therapeutics profitable? | No, Jasper Therapeutics is not profitable. |
| What is the current net income of Jasper Therapeutics? | Jasper Therapeutics' last 12 months net income is ($85M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.